S-1 Plus Leucovorin and Oxaliplatin in Combination with Lentinan as First-line Therapy in Patients with Metastatic Gastric Cancer

Authors: Kenji Ina, Ryuichi Furuta, Megumi Kabeya, Takashi Yoshida, Takae Kataoka, and Satoshi Kayukawa

Journal: Journal of Cancer Research Updates

Study Design: Preliminary study

Participants: 12 patients with metastatic gastric cancer

Intervention: SOL (S-1, oxaliplatin, and leucovorin) combined with lentinan as the first-line regimen. The cycles ranged from 4 to 15.

Outcome Measures:

• Objective response rate (ORR)
• Disease control rate
• Overall survival (OS)
• Adverse effects

Summary: The study aimed to investigate the efficacy and safety of SOL combined with lentinan as a first-line treatment for metastatic gastric cancer. The results showed promising objective response and disease control rates of 58.3% and 91.7%, respectively. One patient achieved complete response and survived for over 23 months. The most common adverse event was peripheral neuropathy, but no severe side effects were observed. The study concluded that SOL combined with lentinan could be a promising option for treating advanced metastatic gastric cancer due to its safety and potential to enhance immune responses.